Mechanical treatment of heart failure: the growing role of LVADs and artificial hearts (original) (raw)
2003, Cleveland Clinic Journal of Medicine
AI-generated Abstract
The increasing prevalence of heart failure, exacerbated by limited treatment options, has led to a growing reliance on left ventricular assist devices (LVADs) and artificial hearts. These devices serve not only as potential bridges to heart transplantation for eligible patients but also offer life-sustaining options for those who are ineligible for transplants. The evolution of these technologies, particularly in pump design and patient management, shows promise for becoming commonplace in the treatment of end-stage heart failure, with considerations of costs and future advancements in device implantation.
Related papers
Mechanical Circulatory Support and the Role of LVADs in Heart Failure Therapy
Clinical Medicine Insights: Cardiology, 2015
Heart failure is epidemic in the United States with a prevalence of over 5 million. The diagnosis carries a mortality risk of 50% at 5 years rivaling many diagnoses of cancer. Heart transplantation, long the “gold standard” treatment for end stage heart failure unresponsive to maximal medical therapy falls way short of meeting the need with only about 2,000 transplants performed annually in the United States due to donor limitation. Left ventricular devices have emerged as a viable option for patients as both a “bridge to transplantation” and as a final “destination therapy”.
The HeartSaver left ventricular assist device: an update
The Annals of Thoracic Surgery, 2001
Background. Ventricular assist devices have been shown to be effective as bridges to transplantation and recovery for patients with end-stage heart failure. Current technology has been limited because of the need for percutaneous connections with controllers. The Heart-Saver ventricular assist device (VAD) (World Heart Corporation, Ottawa, Ontario, Canada) was developed with the intention of having a completely implantable, portable VAD system. The system consists of an electrohydraulic blood pump, internal and external battery power, and a transcutaneous energy transfer and telemetry unit that allows for power transmission through the skin.
Current Options for Mechanical Heart Technology
Journal of Cardiac Surgery, 2008
Heart transplantation remains the treatment of choice for end-stage heart failure despite limited donor availability and allograft durability. Artificial heart technology was initially developed as a replacement for transplantation but the initial experience with these technologies was disappointing. The quest for a total artificial heart has largely been abandoned in favor of ventricular assist devices (VADs). VADs have gained widespread acceptance as bridge t o transplant and bridge t o recovery therapy. After more than a decade of clinical use, several FDA approved device designs have proved effective in treating patients with various causes of heart failure. This review describes the current, clinically available ventricular replacement and assist devices and defines the adult patient populations in which they are useful. The next generation of these devices will soon become available and their clinical utility will likely shape t h e future direction of heart failure therapy. Ultimately t h e concept of a long-term total artificial heart may b e revisited. (J Card Surg 2002;17:81-88)
Journal of Thoracic Disease, 2015
The total artificial heart (TAH) is a form of mechanical circulatory support in which the patient's native ventricles and valves are explanted and replaced by a pneumatically powered artificial heart. Currently, the TAH is approved for use in end-stage biventricular heart failure as a bridge to heart transplantation. However, with an increasing global burden of cardiovascular disease and congestive heart failure, the number of patients with end-stage heart failure awaiting heart transplantation now far exceeds the number of available hearts. As a result, the use of mechanical circulatory support, including the TAH and left ventricular assist device (LVAD), is growing exponentially. The LVAD is already widely used as destination therapy, and destination therapy for the TAH is under investigation. While most patients requiring mechanical circulatory support are effectively treated with LVADs, there is a subset of patients with concurrent right ventricular failure or major structur...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.